Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of OAV101 in spinal muscular atrophy patients
CTR20240883Phase 3Active
- Sponsor
- Novartis
- Start
- May 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of onasemnogene abeparvovec in spinal muscular atrophy (SMA), sponsored by Novartis. Started May 2024; status: active.
02
Drugs
onasemnogene abeparvovec
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on CTR20240883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240883.